Evaluation of the LumiraDx SARS-CoV-2 antigen assay for large-scale population testing in Senegal
- 5 January 2022
- journal article
- Published by Heighten Science Publications Corporation in International Journal of Clinical Virology
- Vol. 6 (1), 001-006
- https://doi.org/10.29328/journal.ijcv.1001041
Abstract
Purpose: Real-time reverse-transcription polymerase chain reaction (RT-PCR)-based testing remains the gold standard for the diagnosis of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Due to the high diagnosis demand of SARS-CoV-2 and the limited resources for RT-PCR testing, especially in Low-Income Countries (LICs), antigen-based methods are being considered as an option. The aim of this study was to assess the performance of LumiraDx SARS-CoV-2 antigen assay for large population screening compared to RT-PCR. Methods: This evaluation was conducted on 4146 participants including travelers and participants under household survey and vaccine evaluation studies before injection of the first dose. Oropharyngeal and nasopharyngeal swaps were collected from each participant into 2 mL of viral transport medium (VTM) and 400 μl of VTM were used to assess the performance of LumiraDx SARS-CoV-2 antigen assay, compared to RT-PCR. Results: The prevalence of SARS-CoV-2 of the cohort was 4.5% with RT-PCR and 4.1% with LumiraDx antigen test. Compared to the RT-PCR, the sensitivity and specificity of the LumiraDx antigen SARS-CoV-2 test were 82,7% [95% CI 74.1-89,7] and 99.9% [95% CI 99.6-99.9] respectively. Given the RT-PCR threshold cycle (Ct) range, the sensitivity was 92.1% [95% CI 84.6-96.3] when the Ct value was below or equal 33 cycles, and 38.1% [95% CI 18.9-61.3] when it was above 33 cycles. The inter-rater reliability showed a kappa coefficient of 0.88 when considering all the patients and 0.94 for Ct values below 33 cycles. Conclusion: Our data have shown that the LumiraDx platform can be considered for large-scale testing of SARS-CoV-2.Keywords
This publication has 28 references indexed in Scilit:
- Correlation Between Relative Nasopharyngeal Virus RNA Load and Lymphocyte Count Disease Severity in Patients with COVID-19Viral Immunology, 2021
- First Reported Nosocomial Outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 in a Pediatric Dialysis UnitClinical Infectious Diseases, 2020
- Epidemiological and initial clinical characteristics of patients with family aggregation of COVID-19Journal of Clinical Virology, 2020
- Virological assessment of hospitalized patients with COVID-2019Nature, 2020
- Diagnosing COVID-19: The Disease and Tools for DetectionACS Nano, 2020
- Fast, portable tests come online to curb coronavirus pandemicNature Biotechnology, 2020
- Viral dynamics in mild and severe cases of COVID-19The Lancet Infectious Diseases, 2020
- SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected PatientsThe New England Journal of Medicine, 2020
- Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injuryScience China Life Sciences, 2020
- Real-Time Reverse Transcription–Polymerase Chain Reaction Assay for SARS-associated CoronavirusEmerging Infectious Diseases, 2004